Microscopic view of immune cells attacking tuberculosis bacteria.

Unlocking TB Immunity: Can a New Antigen Improve Diagnosis?

Mira Elwood monogram
Mira Elwood in Health & Wellness November 2026 • 4 min read.

"Explore how the innovative Rv3615c antigen could revolutionize tuberculosis diagnosis by enhancing T-cell recognition and test sensitivity."


Tuberculosis (TB) remains a significant global health threat, with millions of new cases reported each year. Effective control relies on accurate and early diagnosis, yet current methods often fall short, particularly in detecting latent infections or in immunocompromised individuals.

The body's immune response, especially T-cells, plays a crucial role in combating TB. Identifying specific antigens that trigger these T-cells is key to developing more sensitive diagnostic tools and effective vaccines. While antigens like ESAT-6 and CFP-10 are widely used, there's a constant search for new, more effective markers.

A promising candidate is the Rv3615c antigen, also known as EspC. Studies suggest it's as immunodominant as ESAT-6 and CFP-10, meaning it strongly stimulates the immune system. This raises the possibility of more sensitive T-cell based diagnostics. Now a recent study delves into Rv3615c's ability to activate T-cells and evaluates a diagnostic test combining it with existing antigens.

AI Search Multiple angles on this topic

Discovery of Rv3615c

In 2008, researchers identified Rv3615c as a potentially useful differential diagnostic antigen for the Mycobacterium tuberculosis complex. Rv3615c, also known as Esx-1 substrate protein C (EspC), is encoded outside Region of Difference 1 and resembles CFP-10 and ESAT-6 in size and sequence. Its immunodominance and apparent relevance to cellular immunity supported further investigation for tuberculosis immunodiagnosis and vaccine development.

Rv3615c: A Powerful Trigger for T-Cell Defense

Microscopic view of immune cells attacking tuberculosis bacteria.

The study, published in Tuberculosis, investigated the CTL (cytotoxic T lymphocyte) immunogenicity of the Rv3615c antigen. CTLs are critical for killing infected cells, and their activation indicates a strong immune response. The researchers aimed to understand how well Rv3615c stimulates these cells and whether it could improve TB diagnosis.

Researchers identified that Rv3615c is recognized by a broad range of human leukocyte antigen (HLA) alleles. HLA molecules present antigen fragments to T-cells, and the more HLA types that recognize an antigen, the greater its potential to stimulate an immune response across a diverse population.

Key findings about Rv3615c immunogenicity:
  • Broad HLA Recognition: Rv3615c has multiple peptides recognized by various HLA-A alleles, meaning it can stimulate T-cells in a large portion of the population.
  • Robust CTL Response: The antigen triggers a strong CTL response, indicating its potential to activate the immune system effectively.
  • Cross-Reactivity: Some peptides from Rv3615c can be recognized even in the absence of the original HLA allele, expanding its potential reach.
AI Search Multiple angles on this topic

Persistent Diagnostic Gaps

Recent reviews report that tuberculosis diagnostics still lack reliable tools for predicting progression from Mycobacterium tuberculosis infection to TB disease. Existing approaches also rely heavily on sputum, and universally accessible point-of-care tests remain unavailable. More broadly, differentiating among patients with tuberculosis continues to pose serious diagnostic problems, limiting the impact of even promising antigen-based strategies.

Comparing Candidate Antigens

The 2008 study identified Rv3615c as a useful differential diagnostic antigen for the Mycobacterium tuberculosis complex. Its diagnostic potential was assessed alongside the established tuberculosis-associated antigens ESAT-6 and CFP-10, with the combination described as showing promising results. This comparison positioned Rv3615c as an additional candidate rather than a replacement for existing antigen targets.

Based on these findings, the researchers created a three-antigen cocktail (3-Ag-cocktail) combining Rv3615c with ESAT-6 and CFP-10. This cocktail was then tested in a multi-center, randomized, double-blind study to evaluate its diagnostic performance in a real-world setting.

A Promising Step, But Further Research Needed

The inclusion of the Rv3615c antigen with multiple HLA restricted CTL epitopes would benefit the T-cell based diagnosis of MTB infection. While the 3-Ag-cocktail shows promise, further studies are needed to confirm these findings and optimize its use in different populations and clinical settings. Further research should also investigate the humoral immune responses to Rv3615c to get a more complete understanding of its protective potential.

AI Search Multiple angles on this topic

Toward More Accessible Detection

Future tuberculosis diagnosis must address underdiagnosis and limited access to testing, problems that were worsened by the COVID-19 pandemic. The field also faces a growing incidence of non-tuberculous mycobacterial infections, particularly in the context of an aging population. One proposed direction is an ESAT-6/CFP-10/Rv3615c antigen cocktail intended to enhance T-cell recognition and improve diagnostic accuracy.

How the assay compares with established tests

  • κ = 0.91; 95% CI: 0.85–0.95The new assay’s results closely agreed with T-SPOT.TB results (κ = 0.91; 95% CI: 0.85–0.95).[1]
  • 73%–83% sensitivity; 49%–58% specificityFor active TB, reported IGRA sensitivity ranged from 73% to 83%, while specificity ranged from 49% to 58%.[2]

What the Rv3615c evidence can show

Rv3615c responses were reported as broadly recognized and as specific for M. tuberculosis infection, much like responses to ESAT-6 and CFP-10. That supports its relevance as an immune target, but does not by itself establish how well a test using it performs across different patient groups.[1]

The reported IGRA ranges show that sensitivity and specificity are separate measures, and neither range alone establishes reliable separation of active disease from infection. Other sources explicitly note that IGRA and TST results cannot distinguish active from latent TB.[2] [3]

Where Rv3615c fits among diagnostic results

Agreement with T-SPOT.TB indicates that the new assay produced results similar to an established comparator in the cited evaluation; agreement is not itself a measure of whether either test correctly identifies every case.[1]

Sensitivity varied with the form of active TB: it was highest for culture-positive pulmonary TB and lowest for tuberculosis meningitis. This means a single overall performance figure would not capture the differences reported across these patient groups.[1]

The evidence also describes Rv3615c as containing CD4+ and CD8+ epitopes, with responses specific to M. tuberculosis infection. This adds context about immune recognition, but does not establish that the antigen distinguishes latent infection from active disease.[1] [4]

What remains unresolved for Rv3615c-based tests

  • How does performance vary across forms of active TB, given the difference between culture-positive pulmonary TB and tuberculosis meningitis?[1]
  • Can a test incorporating Rv3615c distinguish active disease from latent infection, when IGRA and TST results generally indicate infection but do not make that distinction?[3] [4]
  • How might concurrent cancer affect the immune response and test sensitivity, given that both were reported to be lower in patients with cancer?[5]

Sources

  1. Evaluation of a New IFN-γ Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting. (pubmed.ncbi.nlm.nih.gov)
  2. Use of the TST and IGRAs for the diagnosis of TB disease - WHO consolidated guidelines on tuberculosis - NCBI BookshelfTwitterFacebookLinkedInGitHubNCBI Insights BlogTwitterFacebookYoutube (www.ncbi.nlm.nih.gov)
  3. ATS/CDC/IDSA Clinical Practice Guidelines for the Diagnosis of Tuberculosis in Adults and Children (www.idsociety.org)
  4. A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis (pmc.ncbi.nlm.nih.gov)
  5. CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

Why is there a need to search for new Tuberculosis (TB) antigens when ESAT-6 and CFP-10 are already in use?

Although ESAT-6 and CFP-10 are widely used antigens for TB diagnosis, the need for new antigens arises because current diagnostic methods often fall short, particularly in detecting latent TB infections or in immunocompromised individuals. The constant search aims to discover more effective markers that can enhance the sensitivity of diagnostic tests and improve the accuracy of detecting TB across diverse populations. An antigen like Rv3615c could potentially fill these gaps by stimulating a stronger immune response.

2

How does the Rv3615c antigen work to stimulate the immune system against Tuberculosis?

The Rv3615c antigen, also known as EspC, stimulates the immune system by triggering T-cells, specifically cytotoxic T lymphocytes (CTLs). These CTLs are crucial for killing cells infected with TB. Rv3615c is recognized by a broad range of human leukocyte antigen (HLA) alleles. HLA molecules present fragments of the antigen to T-cells, initiating an immune response. The ability of Rv3615c to be recognized by multiple HLA types means it can stimulate T-cells in a large portion of the population, making it a potentially effective diagnostic tool.

3

What is the significance of 'broad HLA recognition' in the context of the Rv3615c antigen and its potential use in Tuberculosis diagnosis?

Broad HLA recognition is significant because it means that the Rv3615c antigen can stimulate T-cells in a larger and more diverse population. Human Leukocyte Antigens (HLA) present antigen fragments to T-cells, initiating an immune response. If an antigen is recognized by a wide range of HLA alleles, it can activate T-cells in a greater proportion of individuals, regardless of their genetic background. This is crucial for a diagnostic tool to be effective globally, as HLA allele distributions vary across different ethnic and geographical groups. This broad recognition enhances the antigen's utility in T-cell-based diagnostics for TB.

4

What is the '3-Ag-cocktail,' and how does it aim to improve Tuberculosis diagnosis?

The '3-Ag-cocktail' is a combination of three antigens: Rv3615c, ESAT-6, and CFP-10. This cocktail aims to improve TB diagnosis by leveraging the strengths of each antigen to stimulate a more robust and comprehensive immune response. The inclusion of Rv3615c with ESAT-6 and CFP-10 could potentially increase the sensitivity of diagnostic tests, leading to earlier and more accurate detection of TB infections, including latent infections. The combination of antigens may also broaden the test's applicability across diverse populations with varying HLA types.

5

What future research is needed to fully understand the potential of the Rv3615c antigen in combating Tuberculosis?

To fully understand the potential of the Rv3615c antigen, further studies are needed to confirm the initial findings and optimize its use in different populations and clinical settings. It's also important to investigate the humoral immune responses to Rv3615c. Understanding both the T-cell and antibody responses will provide a more complete picture of its protective potential. Additional research should focus on evaluating the diagnostic performance of the 3-Ag-cocktail in real-world settings, as well as exploring its use in vaccine development. Studies in specific populations, such as children and immunocompromised individuals, are also needed.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.